
CASE STUDY

indero

Phase 3 **Pediatric Atopic Dermatitis (AD)** Study



Indero successfully managed this Phase 3 AD study, resulting in:

- Patient recruitment completed six and a half months early
- Achieved same-day or next-day activation for most of the 47 sites

STUDY **CHARACTERISTICS**

Study Phase: 3

Study Design: 8-week randomized, double-blind placebo-controlled study followed by an open label extension (OLE) of 48 weeks

Patient Population: Pediatric (three months to two years) AD

IP Route of Administration: Topical

Total Enrollment: 187 patients, 47 sites (United States & Canada)

CHALLENGES AND **SOLUTIONS**

Challenge #1: Insufficient sites serving target population	**Solution:** Indero adjusted physician referral pathway, and conducted targeted recruitment campaign
Challenge #2: Same-day site activation required	**Solution:** Indero's agility achieved goal at most sites
Challenge #3: Sponsor acquisition brought many new faces	**Solution:** Indero's adaptable team minimized the impact

STRATEGIES FOR **SUCCESS**

Dermatologic expertise within Indero meant knowing which sites to select, resulting in exceeding patient enrollment goals and timelines.

Pivot to appropriate physician referral pathway by Indero's site selection team to get the right investigators to read the right feasibility questionnaire.

Leveraging Indero's in-house Clinago platform and patient recruitment expertise to conduct an impactful central advertising campaign that accelerated enrollment.

New study startup model customized for the sponsor by Indero's study startup team.